Oragenics Inc (OGEN) Quote

OGEN under $2

OGEN 10Q due 3/19

China Dump

News just hit! Oragenics Issues Update to Shareholders:
https://www.otcmarkets.com/stock/OGEN/news/story?e&id=2676834

OGEN steady rise looks like this biotech is ready to run!

Will this turd float to the surface? :)

Maybe not. :)

Don't madder they will short it down to nothing

Surfs up. ::)

Chart setup perfectly here -> time is koming for the super spike

https://stockcharts.com/h-sc/ui?s=ogen

Hey whatever it takes to see it rise to the moon but wow hats off to your sacrifice. :)

,,,,,,,I’m out

3/22 Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

"“We are thrilled to have begun this pivotal study with Frontage, a premier drug development contract research organization, and are thankful to the acceleration Frontage has offered our important IND-enabling study. We believe the results from this rabbit toxicology study will support our development strategy for our intranasal COVID-19 vaccine candidate, NT-CoV2-1. The intranasal delivery route is particularly relevant as it may further reduce transmission of the virus and provide a needle-free delivery option. The findings from this preclinical toxicology study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration,” said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics."


https://ir.oragenics.com/press-releases/detail/142

KABOOM !! ve got movement!!

Looks like word is getting out. :)

I agree. The buy consensus is at 83%.3 days ago. I think info is near. :)

HUGE insider buy

OGEN HOD

lets get this back over $1

Oragenics (OGEN) Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant

Agreement extends current licensing and collaboration agreement to include rapid production of Omicron-specific intranasal vaccine candidates

TAMPA, Fla., December 20, 2021--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant. The NRC cell expression technologies provide Oragenics with a platform that can generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern. This platform should allow production of cell lines within six to eight weeks of spike gene sequence availability, compared with six to nine months for traditional production of such cell lines. The NRC technologies, developed with support from the NRC’s Pandemic Response Challenge program, will expedite the evaluation of an Omicron-specific Terra-CoV-2 candidate in preclinical and clinical studies.

"Oragenics is well-positioned to develop an Omicron-specific intranasal vaccine thanks to our successful, on-going collaboration with the NRC," said Frederick W. Telling, Ph.D., Oragenics’ Executive Chairman. "We had anticipated the need for rapid development of COVID-19 vaccine candidates against new variants and can leverage the NRC cell expression platform to address Omicron and future variants."

Oragenics recently demonstrated the protection of hamsters against SARS-CoV-2 with the intranasal Terra-CoV-2 candidate, which strongly supports the further development into an IND-enabling GLP toxicology study and a first-in-human Phase 1 clinical study.

https://finance.yahoo.com/news/oragenics-extends-collaboration-national-research-130000929.html

Oragenics Announces Positive COVID-19 Challenge Study Results

Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate

Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.

Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge. By contrast, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads. The vaccines delivered by intranasal and intramuscular routes generated immune responses as measured by multiple assays.

"The very positive results from this hamster challenge study fully support our further development of either the intranasal or intramuscular routes of administration, however we plan to focus on the intranasal delivery route for the Terra CoV-2 vaccine due to the relative lack of competition and anticipated advantages of intranasal vaccine delivery, such as reducing viral transmission, needle-free administration, and ease of distribution, as well as the potential for conferred mucosal immunity which is presently being studied. The findings from this second preclinical study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration, expected to be made in the second quarter of 2022, and should facilitate advancement of the program into human clinical studies," said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.

https://finance.yahoo.com/news/oragenics-announces-positive-covid-19-130000711.html

News!

ORAGENICS is really on a good way to achieve soon $ 10 or more!!!!!!!!!!!!!!!!!!!!!!!!!!

Opps good call. I own both and posted on the wrong board. :)

How does that help OGEN?

Qiagen has received emergency use authorization from the U.S. Food and Drug Administration for its QIAreach SARS CoV-2 Antigen Test, which is designed for environments that require a high volume of fast and accurate test results. :)

OGEN will be a player....opportunity knocks.

Been a nice atm.


OGEN

What will happen today? Morning dip into low 70s to add?
Every time this stock runs….she sells off Next couple days. We shall see

Here comes eod volume

$100-$200M from Canadian govt funding ?

Should thin out soon

EPIC :)

Could be epic

Big day looming here after OGEN announcement of work with Canadian Government on fast track vaccine alternatives.

Nice day here. Need to get back to a buck soon

O-0

OGEN cover time

* * $OGEN Video Chart 04-23-2021 * *

Link to Video - click here to watch the technical chart video

It's all about the therapeutics, peutics, peutics. :)

It's time for the CEO to get his head out of his toxic azz.

Past time.................But I can wait.

GO OGEN

"PEACE"

Time to.move up

Sorry, spike....

$OGEN Meandering up from the morning low on low volume. Any upcoming catalysts expected?

https://www.stockscores.com/charts/charts/?ticker=OGEN



below average volume
https://ih.advfn.com/stock-market/AMEX/oragenics-OGEN/historical

Filled at the gap............

GO OGEN

"PEACE"

Breaking news OGEN upgraded with a $2.75 PT

After-Hours Stock Movers 03/24: (RH) (OGEN) (FUL) Higher; (RAD) (EVFM) (KBH) Lower (more...)

March 24, 2021 5:40 PM

?

After-Hours Stock Movers

Rite Aid Corporations (NYSE: RAD) 17.9% LOWER; fourth quarter 2021 financial results were significantly impacted by a soft cough, cold and flu season, ongoing impacts related to COVID-19 and challenging weather conditions. As a result, the Company is updating its guidance for the fiscal year ended February 27, 2021.

Do this one thing with your money by April 30th

Sponsored By Stansberry Research

The next few weeks could affect your wealth for the next decade. Millions of Americans will be taken by surprise. Here’s what’s coming.

Evofem Biosciences, Inc. (NASDAQ: EVFM) 11.2% LOWER; announced that it intends to offer and sell, subject to market and other conditions, $30 million of shares of its common stock in an underwritten public offering

RH (NYSE: RH) 9.4% HIGHER; reported Q4 EPS of $5.07, $0.31 better than the analyst estimate of $4.76. Revenue for the quarter came in at $812.4 million versus the consensus estimate of $797.27 million.

Oragenics (NYSE: OGEN) 8% HIGHER; Ascendiant Capital assumes coverage with a Buy rating and a price target of $2.75.

H.B. Fuller (NYSE: FUL) 6.2% HIGHER; reported Q1 EPS of $0.66, $0.18 better than the analyst estimate of $0.48. Revenue for the quarter came in at $726 million versus the consensus estimate of $680.98 million.

KB Home (NYSE: KBH) 5.8% LOWER; reported Q1 EPS of $1.02, $0.10 better than the analyst estimate of $0.92. Revenue for the quarter came in at $1.14 billion versus the consensus estimate of $1.21 billion.

D8 Holdings Corp (NYSE: DEH) 2.7% HIGHER; Vicarious Surgical, a developer of medical robot tech that's backed by Bill Gates, is in talks to go public through a merger with blank-check firm D8 Holdings Corp (NYSE: DEH), according to a report from Bloomberg, citing a person with knowledge of the matter.

Full House Resorts, Inc. (Nasdaq: FLL) 2.7% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Wall Street Connected: Oriental Culture Holdings

Wall Street Connected: Oriental Culture Holdings

 

Latest Videos

?

Wall Street Connected: Oriental Culture Holdings

?

Looking at 10-Year Yields

?

Higher Yields, Stronger Dollar?

?

Categories

Special Reports

?

?

The gap set around 85 will have to eventually closed and then the share price recover before another substantial move upward?

Waiting to see what event initialized that move.....Another share offering, warrants, sells?

WE WILL WAIT TOO SEE.........

'peace'

However, more positive news trumps all...

* * $OGEN Video Chart 03-09-2021 * *

Link to Video - click here to watch the technical chart video

Onward and upward. :)